This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Massachusetts Medical School is focused on understanding how the gut microbiome influences neurodegeneration and protects against Alzheimer's disease. The $647,979 award, effective September 30, 2024 through August 31, 2025, will leverage the C. elegans model system to: Determine how bacterial production of vitamin B12 protects against neurodegeneration pathways. Examine...
This $679,424 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports preclinical studies to evaluate the efficacy of a novel nanoligomer treatment for reducing neuroinflammation and protecting against cognitive decline in mouse models of brain aging and Alzheimer's disease. The research aims to determine the ideal application of the NF-kB/NLRP3-targeted nanoligomer treatment, whether for prevention during aging or treatment of pathology, and to...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
The University of South Florida received a $3,385,215 Project Grant award from the National Institute on Aging, part of the National Institutes of Health within the Department of Health and Human Services. The grant was awarded under the Aging Research program (CFDA 93.866) to fund research titled "Microbial Therapy Improves Gut Permeability to Reduce Cognitive Decline and Alzheimer's Disease." The grant will support research from August 2021 through July 2024 to study the impact of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to investigate the role of pathogen-induced cellular senescence and blood-brain barrier dysfunction in the development and progression of Alzheimer's disease. The $794,341 award, effective from January 1, 2025 through December 31, 2029, will be conducted by the University of Illinois in Chicago. The research aims to leverage experimental mouse models, molecular characterization of...
This federal Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), aims to develop an effective targeted delivery system for the bioactive curcuminoids curcumin and bisdemethoxycurcumin to treat Alzheimer's disease and other neuroinflammatory disorders. The $1,006,428 award, spanning September 2024 to August 2025, will support the optimization of folate-functionalized exosomal formulations for trans-spinal delivery of these curcuminoids to...
This National Institute on Aging (NIA) Project Grant award for $734,778 under the Aging Research program (CFDA 93.866) is supporting research to develop a novel, scalable allogeneic cell therapy platform capable of addressing both tau-mediated pathology and associated inflammation in Alzheimer's disease and related dementias. The project aims to engineer chimeric antigen receptor (CAR) macrophages derived from human induced pluripotent stem cells (iPSCs) to target pathogenic tau protein and...
This federal Project Grant award of $696,896.00 from the National Institute on Aging (CFDA 93.866 Aging Research) aims to study the impact of the gut microbiome on B cell-mediated neuroinflammation in cerebral amyloid angiopathy (CAA). The research will be conducted by the University of Texas Health Science Center at Houston and will: Investigate whether CAA induces B cell-driven inflammation in the brain, Examine if CAA-induced gut dysbiosis can promote B cell-mediated neuroinflammation that...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,189,692 in funding to Bloom Science, Inc. to develop a neuroprotective engineered bacteria for the treatment of Alzheimer's disease. The project aims to leverage the probiotic bacterium Akkermansia muciniphila and engineer it to produce anti-inflammatory compounds such as butyrate, beta-hydroxybutyrate, and tauroursodeoxycholic acid (TUDCA) to reduce neuroinflammation and slow disease progression. The award period runs from September 2024 to May 2025 and involves screening Akkermansia isolates, engineering the target metabolites into the bacterial genome, and conducting preclinical characterization studies in mouse models of Alzheimer's disease.